C-Path encouraged by FDA to move forward on type 1 diabetes biomarker initiative
Biomarker potentially could identify individuals at risk of developing T1D TUCSON, Ariz., December 18, 2018 -- Critical Path Institute (C-Path) announced today that its Type...










